In chronic myeloid leukemia cells, the knockdown of ATG4B suppresses autophagy and reduces the survival of cells, which increases the sensitivity of cancer cells to chemotherapy treatment [31,32]. This evidence concerns the gene ATG4B and chronic myelogenous leukemia, BCR-ABL1 positive.